Literature DB >> 18354166

Loss of IFN-gamma enables the expansion of autoreactive CD4+ T cells to induce experimental autoimmune encephalomyelitis by a nonencephalitogenic myelin variant antigen.

Joseph J Sabatino1, John Shires, John D Altman, Mandy L Ford, Brian D Evavold.   

Abstract

MHC variant peptides are analogues of immunogenic peptides involving alterations of the MHC-binding residues, thereby altering the affinity of the peptide for the MHC molecule. Recently, our laboratory demonstrated that immunization of WT B6 mice with 45D, a low-affinity MHC variant peptide of MOG(35-55), results in significantly attenuated experimental autoimmune encephalomyelitis (EAE), yet IFN-gamma production is comparable to myelin oligodendrocyte glycoprotein (MOG)(35-55)-immunized mice. In light of these findings, we asked whether IFN-gamma was required for the reduced encephalitogenicity of the weak ligand 45D in EAE. In this study, we report that immunization of mice deficient in IFN-gamma or its receptor with 45D exhibit significant EAE signs compared with 45D-immunized wild-type B6 mice. Moreover, 45D-immunized IFN-gamma(-/-) and IFN-gammaR(-/-) mice demonstrate MOG tetramer-positive CD4(+) T cells within the CNS and display substantial numbers of MOG-specific CD4(+) T cells in the periphery. In contrast, wild-type mice immunized with 45D exhibit reduced numbers of MOG-specific CD4(+) T cells in the periphery and lack MOG tetramer- positive CD4(+) T cells in the CNS. Importantly, the increased encephalitogenicity of 45D in mice lacking IFN-gamma or IFN-gammaR was not due to deviation toward an enhanced IL-17-secreting phenotype. These findings demonstrate that IFN-gamma significantly attenuates the encephalitogenicity of 45D and are the first to highlight the importance of IFN-gamma signaling in setting the threshold level of responsiveness of autoreactive CD4(+) T cells to weak ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354166     DOI: 10.4049/jimmunol.180.7.4451

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Authors:  Joseph J Sabatino; Kristen M Rosenthal; Brian D Evavold
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-11       Impact factor: 4.147

2.  Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread.

Authors:  Anna E Kersh; Lindsay J Edwards; Brian D Evavold
Journal:  J Immunol       Date:  2014-09-29       Impact factor: 5.422

3.  Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17.

Authors:  Gizi Wildbaum; Yaniv Zohar; Nathan Karin
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

4.  Absence of IFN-γ increases brain pathology in experimental autoimmune encephalomyelitis-susceptible DRB1*0301.DQ8 HLA transgenic mice through secretion of proinflammatory cytokine IL-17 and induction of pathogenic monocytes/microglia into the central nervous system.

Authors:  Ashutosh K Mangalam; Ningling Luo; David Luckey; Louisa Papke; Alyssa Hubbard; Arika Wussow; Michele Smart; Shailendra Giri; Moses Rodriguez; Chella David
Journal:  J Immunol       Date:  2014-10-22       Impact factor: 5.422

5.  GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibitory antigen presentation.

Authors:  S M Touhidul Islam; Alan D Curtis; Najla Taslim; Daniel S Wilkinson; Mark D Mannie
Journal:  J Immunol       Date:  2014-07-21       Impact factor: 5.422

6.  Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics.

Authors:  Rahmawati Ridwan; Paul Kiptoo; Naoki Kobayashi; Scott Weir; Michael Hughes; Todd Williams; Rondang Soegianto; Teruna J Siahaan
Journal:  J Pharmacol Exp Ther       Date:  2009-12-21       Impact factor: 4.030

7.  Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis.

Authors:  Yang Mei; Faming Pan; Jing Gao; Rui Ge; Zhenhua Duan; Zhen Zeng; Fangfang Liao; Guo Xia; Sheng Wang; Shengqian Xu; Jianhua Xu; Li Zhang; Dongqing Ye
Journal:  Clin Rheumatol       Date:  2010-12-17       Impact factor: 2.980

8.  Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination.

Authors:  Ning Jiang; Jun Huang; Lindsay J Edwards; Baoyu Liu; Yan Zhang; Carrie D Beal; Brian D Evavold; Cheng Zhu
Journal:  Immunity       Date:  2011-01-20       Impact factor: 31.745

9.  Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease.

Authors:  Jennifer D Hood; Veronika I Zarnitsyna; Cheng Zhu; Brian D Evavold
Journal:  J Immunol       Date:  2015-09-18       Impact factor: 5.422

10.  NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease.

Authors:  Lori Blanchfield; Joseph J Sabatino; Laurel Lawrence; Brian D Evavold
Journal:  J Immunol       Date:  2017-09-08       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.